ERAS NASDAQ
Erasca, Inc.
1W: +3.4%
1M: -10.0%
3M: -21.8%
YTD: +310.6%
1Y: +567.0%
3Y: +579.3%
5Y: -23.4%
$14.74
+0.16 (+1.10%)
Weekly Expected Move ±7.5%
$13
$14
$15
$16
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
4 relationships4
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2021-11-23
Earliest Filing
2024-05-16
Latest Filing
partner: 3
licensee: 1
Counterparties (Filed by ERAS)
4 relationshipsCompanies named in ERAS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Guangzhou Joyo Pharmatech Co., Ltd. | — | partner | Erasca entered into an exclusive license agreement to develop and commercialize pan-RAS inhibitors. | 2024-05-16 | View |
| Medshine Discovery Inc. | — | partner | Erasca entered into an exclusive license agreement to develop and commercialize pan-KRAS inhibitors. | 2024-05-16 | View |
| Novartis Pharma AG | NVSEF | licensee | Erasca, Inc. entered into an exclusive license agreement to develop and commercialize naporafenib, issuing shares and ma | 2022-12-09 | View |
| BMR-Road to the Cure LP | — | partner | Counterparty to a Second Amendment to Lease regarding the Company's corporate headquarters relocation. | 2021-11-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-24 | Other Events | View | |
| 2026-08-11 | Earnings Release; Exhibits | View | |
| 2026-08-10 | Officer/Director Change | View | |
| 2026-07-14 | Other Events; Exhibits | View | |
| 2026-07-13 | Other Events | View | |
| 2026-07-01 | Shareholder Vote | View | |
| 2026-04-27 | Regulation FD; Other Events | View | |
| 2026-04-27 | Other Events | View | |
| 2026-04-21 | Other Events | View | |
| 2026-03-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-29 | Other Events | View | |
| 2026-01-22 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-20 | Results of Operations and Financial Condition | View | |
| 2026-01-12 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-26 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-20 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-13 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR